Nilaya Varma, Co-founder and Group CEO, Primus Partners, highlighted that Philogen’s withdrawal of the EU marketing application for Nidlegy marks an untimely setback for Sun Pharma. While it may not have immediate financial implications, it poses risks to the company’s long term strategic presence in Europe and Australia. This development follows closely on the heels of another disappointment as SCD44's failure triggered an 18% drop in Sun Pharma’s stock earlier this month.